Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ALXO
ALX ONCOLOGY HOLDINGS INC.
NASDAQ
$2.00
▼ DOWN 2.44% (-0.05)

KEY STATISTICS

Market Cap$269.13 M
52w High$2.66
52w Low$0.96
Dividend Yield—
Frequency—
P/E-1.77
Volume639.79K
Shares Out.134.56M

COMPANY

LEADERSHIP

Jason W. Lettmann
CHIEF EXECUTIVE
Jason W. Lettmann

COMPENSATION 2026

Salary$724,500
Stock Awards$0
Incentive Plan Pay$298,856
All Other Comp.$0
Total$2,470,844

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 17, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
48

PRICE TARGET

Target High$38.00
Target Low$1.50
Target Median$21.00
Target Consensus$17.90

UPCOMING EARNINGS

DateNov 6, 2026
DayFriday
Rev. Est.—
NOV
6
FRI

PRICE

$2.00 ▼ DOWN 2.44% (−$0.05)
$1.98$2.00$2.02$2.049:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM2.00

About ALX Oncology Holdings Inc.

https://www.alxoncology.com ↗

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company developing therapies like ALX148 for various cancers, with collaborations and licenses to advance cancer immunotherapy.

INDUSTRY

Biotechnology

A PRODUCT ALX ONCOLOGY HOLDINGS INC. IS KNOWN FOR

Evorpacept
Evorpacept

Evorpacept is a clinical-stage CD47 blocker designed to enhance immune detection of cancer cells, currently in trials for gastric, head and neck, and breast cancers.

COMPETITORS

COMPETITOR
GILD COMPARE
MGNX COMPARE
NBP COMPARE
PFE COMPARE
STTK COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
53
LISTED HERE
12
RANKED BY POSITION SIZE
VTS.AX
0.00% · 3.6M
IWM
0.01% · 2.6M
GSSC
0.03% · 181.6K
FESM
0.00% · 119.2K
XRS2.DE
0.01% · 98.5K
R2SC.L
0.00% · 91.2K
QQQS
0.52% · 58.9K
AVSC
0.00% · 58.3K
RSSL
0.01% · 51.2K
CN
CNCR
3.21% · 25.6K
DFMC
0.00% · 7.8K
URTY
0.00% · 4.4K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
57.73%
HOLDERS
95
TOP 12 OF 95 · RANKED BY POSITION SIZE
Ra Capital Management, L.P.
13.0M sh · $26.09M
Tcg Crossover Management, LLC
13.0M sh · $26.09M
Venbio Partners LLC
12.9M sh · $25.83M
Redmile Group, LLC
8.0M sh · $15.97M
Blackstone Inc.
5.8M sh · $11.71M
Driehaus Capital Management LLC
5.7M sh · $11.5M
Marshall Wace, Llp
3.8M sh · $7.51M
Millennium Management LLC
3.2M sh · $3.62M
Vivo Capital, LLC
3.2M sh · $6.39M
Almitas Capital LLC
3.2M sh · $6.36M
5am Venture Management, LLC
3.1M sh · $6.13M
Orbimed Advisors LLC
2.9M sh · $5.75M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Lettmann Jason
Sale · 2.2K shares
2026-08-17
★
OFFICER: SVP, FINANCE AND CAO
Wong Shelly
Sale · 573 shares
2026-08-17
★
OFFICER: SVP, FINANCE AND CAO
Wong Shelly
Sale · 1.4K shares
2026-07-01
★
Knight Jeff E.
— · —
2026-04-13

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
OVERWEIGHT 1
2 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Piper Sandler OVERWEIGHT

SECTORS PEERS

PEERPRICE
KYMR$118.15COMPARE
STOK$31.62COMPARE
GLUE$13.38COMPARE
ANNX$4.97COMPARE
BCYC$4.20COMPARE
ARTV$11.17COMPARE
STRO$25.43COMPARE
IMUX$15.19COMPARE